ResearchSafe

FDA peptide panel has industry ties, AP flags the conflict

Posted by leah_j in Research & News - 3 points, 4 comments.

https://www.cbsnews.com/news/fda-peptides-review-regulations-unapproved-therapies

AP just dropped a piece on the FDA's peptide panel noting that several doctors involved have ties to companies selling peptide formulas. That detail matters a lot to me. If people shaping the 503A list stand to profit from the substances on that list, the whole "evidence-based" framing kind of falls apart?

I've been sitting with the FDA news for weeks and honestly I'm more skeptical than excited. Loosening access without solid trial data feels backwards to me. We'd want safety data FIRST, not after compounding expands and things go sideways. The Stanford piece from a few days ago basically said the same thing, most popular peptides out there have no real human trials behind them.

Anyone else feel like this is being rushed for political reasons more than science ones? Curious how people here are weighing the risk of a bad outcome against the upside of easier access?

Comments

  • fasted_scientist: Big same honestly. The conflict thing is what kills me about panels like this in general, once money's on the table "evidence-based" just becomes a sticker they slap on whatever direction benefits them. Doesn't mean every recommendation is corrupt, but it means we should be reading the minutes, not just the headline. The rush angle is interesting too though. Loosening access without proper human data is a weird order of operations if you actually care about safety. Usually the playbook is: tria
  • leah_j: Yeah the "sticker" thing is exactly it. Like nobody on the panel is probably twirling a mustache, but if their clinic sells what they're voting to include, that's still a bias worth naming? And right, skipping straight to access with no real human data is just backwards. We get the side effects AFTER everyone's already a guinea pig, which is a hell of a way to run a policy. Stanford said basically the same. Are you tracking any of the named panelists' financial disclosures specifically? I have
  • restless_swims: Yeah the rush bit is exactly what's making me uneasy too. Not gonna lie, when the announcement dropped I wanted to be excited, access has been a nightmare for ages. But skipping proper safety data just to widen availability? That's not how it's supposed to work, and it makes the conflict stuff look even worse 🧠
  • leah_j: Right?? Access being easier is genuinely appealing, I've been there trying to source decent stuff and it sucks. But easier access + no real safety data + panel with skin in the game is just a bad combo. Did you catch who exactly is on the panel with ties? I haven't seen a full list yet, just the AP mention.

Community discussion - research and educational context only. Not medical advice.